In addition, all subtypes showed decreased expression of genes related to ADP ribosylation (Figure 2), which may influence the efficacy of PARP inhibitors among patients with more progressed tumors; although expression of the primary targets of PARP inhibitors (PARP1 and PARP2) either remained level or increased in expression during cancer progression. Here, PARP1 is linked to cancer.